Aktis Oncology
Aktis Oncology is a clinical-stage biotechnology company developing targeted alpha radiopharmaceuticals for various solid tumors. Their lead program targets Nectin-4, a tumor-associated antigen. The company utilizes a proprietary miniprotein radioconjugate platform designed for maximized tumor killing and minimized side effects.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $175M
Date: 30-Sep-2024
Investors: RA Capital Management, RTW Investments, Janus Henderson Investors, funds and accounts advised by T. Rowe Price Associates, Inc., Avidity Partners, an undisclosed life sciences-focused investment fund, Bristol Myers Squibb, Eli Lilly and Company, MRL Ventures Fund
Markets: Biotechnology, Oncology, Radiopharmaceuticals, Health Care, Life Science
HQ: Boston, Massachusetts, United States
Founded: 2021
Website: https://www.aktisoncology.com
LinkedIn: https://www.linkedin.com/company/aktis-oncology
Crunchbase: https://www.crunchbase.com/organization/aktis-oncology
Leave a Comment
Comments
No comments yet.